Literature DB >> 10651749

The effects of growth hormone replacement therapy on overnight metabolic fuels in hypopituitary patients.

E Kousta1, A Chrisoulidou, N J Lawrence, V Anyaoku, K A Al-Shoumer, D G Johnston.   

Abstract

OBJECTIVE: Hypopituitary adults on conventional replacement have low concentrations of metabolic fuels throughout the night, possibly related to GH deficiency or to decreased cortisol levels overnight. We investigated whether GH replacement corrects the overnight fuel deficiency.
DESIGN: We measured circulating levels of metabolic fuels: glucose, non-esterified fatty acids (NEFA), glycerol and 3-hydroxybutyrate (3-OHB) and insulin concentrations over 24 h (from 0730 h to 0700 h) in hypopituitary adults before and after GH treatment in a randomized double-blind placebo-controlled trial of 3 months' duration. PATIENTS: Thirteen hypopituitary patients, 8 women and 5 men, were studied.
RESULTS: Six patients (4 women and 2 men) received GH and 7 patients (4 women and 3 men) were allocated to receive placebo. There was no difference in fasting (0730 h), area under the curve (AUC) between 2400 h and 0700 h (overnight) and AUC over 24 h for plasma glucose, 3-OHB, glycerol and insulin concentrations as a result of GH treatment. Fasting and overnight AUC for NEFA were significantly higher on GH treatment ((mean +/- SEM) 243 +/- 29 vs. 446 +/- 90 micromol/l, P = 0.03, 1522 +/- 208 vs. 2167 +/- 123 micromol/l H, P = 0.046, respectively), but AUC over 24 h was not affected significantly. No significant changes in any fuel were seen in the placebo group. The changes in fasting, overnight and 24 h AUC for glucose, 3-OHB, glycerol and insulin levels with GH and with placebo for 3 months were similar. The changes in fasting and overnight AUC for NEFA before and after 3 months were significantly different in the group treated with GH vs. the group treated with placebo (median (lower-upper quartile) 104 (90-276) vs. -89 (-98 to 26) micromol/l, P = 0.002; 633 (263-967) vs. -895 (-1379 to -494) micromol/l h, P = 0.002, respectively), but the changes in 24-h AUC for NEFA were not significant between the two groups.
CONCLUSIONS: GH replacement in hypopituitary adults increases fasting and overnight (between 2400 h and 0700 h) non-esterified fatty acid concentrations, consistent with the known lipolytic effect of GH. GH did not influence the concentrations of other metabolic fuels or insulin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10651749     DOI: 10.1046/j.1365-2265.2000.00862.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

Review 1.  Long-term growth hormone replacement therapy in hypopituitary adults.

Authors:  Johan Verhelst; Roger Abs
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Increase in serum pregnancy-associated plasma protein-A is correlated with increase in cardiovascular risk factors in adult patients with growth hormone deficiency.

Authors:  Linman Li; Wei Ren; Jinchao Li; Jingjing Liu; Lingli Wang; Xiaoya Zheng; Dezhen Liu; Sufang Li; Rhonda Souvenir; Jiping Tang
Journal:  Endocrine       Date:  2012-05-29       Impact factor: 3.633

3.  Reduced abdominal adiposity and improved glucose tolerance in growth hormone-treated girls with Turner syndrome.

Authors:  Nicole Wooten; Vladimir K Bakalov; Suvimol Hill; Carolyn A Bondy
Journal:  J Clin Endocrinol Metab       Date:  2008-03-18       Impact factor: 5.958

4.  Impact of Long-Term Growth Hormone Replacement Therapy on Metabolic and Cardiovascular Parameters in Adult Growth Hormone Deficiency: Comparison Between Adult and Elderly Patients.

Authors:  Elisabetta Scarano; Enrico Riccio; Teresa Somma; Rossana Arianna; Fiammetta Romano; Elea Di Benedetto; Giulia de Alteriis; Annamaria Colao; Carolina Di Somma
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-25       Impact factor: 5.555

Review 5.  Circadian regulation of metabolic homeostasis: causes and consequences.

Authors:  Graham R McGinnis; Martin E Young
Journal:  Nat Sci Sleep       Date:  2016-05-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.